An update on bimatoprost in glaucoma therapy

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bimatoprost, a prostamide, effectively lowers intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. In clinical trials, bimatoprost has demonstrated superiority to the β-adrenergic antagonist timolol and has consistently provided ∼ 1 - 2 mmHg greater mean IOP lowering than the prostaglandin latanoprost. Bimatoprost is more effective than either timolol or latanoprost in allowing patients to reach the low target pressures that best protect the visual field. Patients on bimatoprost therapy achieve low pressures throughout the day and night. Moreover, 1-year trials have shown that the efficacy of bimatoprost is sustained with long-term use. The most common side effects have been conjunctival hyperaemia, graded as trace or mild, and eyelash growth. No safety concerns have arisen in postmarketing surveillance. Bimatoprost appears to be a valuable new agent for glaucoma therapy.

Original languageEnglish
Pages (from-to)1753-1762
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number12
DOIs
StatePublished - Dec 1 2002

Fingerprint

Glaucoma
latanoprost
Timolol
Intraocular Pressure
Therapeutics
Eyelashes
Pressure
Ocular Hypertension
Adrenergic Antagonists
Open Angle Glaucoma
Hyperemia
Visual Fields
Prostaglandins
Bimatoprost
Clinical Trials
Safety
Growth

Keywords

  • Bimatoprost
  • Glaucoma
  • Intraocular pressure
  • Ocular hypertension
  • Prostamide
  • Target pressure

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

An update on bimatoprost in glaucoma therapy. / Cantor, Louis.

In: Expert Opinion on Pharmacotherapy, Vol. 3, No. 12, 01.12.2002, p. 1753-1762.

Research output: Contribution to journalArticle

@article{e09a944348884541ad7dba74b3dd1086,
title = "An update on bimatoprost in glaucoma therapy",
abstract = "Bimatoprost, a prostamide, effectively lowers intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. In clinical trials, bimatoprost has demonstrated superiority to the β-adrenergic antagonist timolol and has consistently provided ∼ 1 - 2 mmHg greater mean IOP lowering than the prostaglandin latanoprost. Bimatoprost is more effective than either timolol or latanoprost in allowing patients to reach the low target pressures that best protect the visual field. Patients on bimatoprost therapy achieve low pressures throughout the day and night. Moreover, 1-year trials have shown that the efficacy of bimatoprost is sustained with long-term use. The most common side effects have been conjunctival hyperaemia, graded as trace or mild, and eyelash growth. No safety concerns have arisen in postmarketing surveillance. Bimatoprost appears to be a valuable new agent for glaucoma therapy.",
keywords = "Bimatoprost, Glaucoma, Intraocular pressure, Ocular hypertension, Prostamide, Target pressure",
author = "Louis Cantor",
year = "2002",
month = "12",
day = "1",
doi = "10.1517/14656566.3.12.1753",
language = "English",
volume = "3",
pages = "1753--1762",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - An update on bimatoprost in glaucoma therapy

AU - Cantor, Louis

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Bimatoprost, a prostamide, effectively lowers intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. In clinical trials, bimatoprost has demonstrated superiority to the β-adrenergic antagonist timolol and has consistently provided ∼ 1 - 2 mmHg greater mean IOP lowering than the prostaglandin latanoprost. Bimatoprost is more effective than either timolol or latanoprost in allowing patients to reach the low target pressures that best protect the visual field. Patients on bimatoprost therapy achieve low pressures throughout the day and night. Moreover, 1-year trials have shown that the efficacy of bimatoprost is sustained with long-term use. The most common side effects have been conjunctival hyperaemia, graded as trace or mild, and eyelash growth. No safety concerns have arisen in postmarketing surveillance. Bimatoprost appears to be a valuable new agent for glaucoma therapy.

AB - Bimatoprost, a prostamide, effectively lowers intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. In clinical trials, bimatoprost has demonstrated superiority to the β-adrenergic antagonist timolol and has consistently provided ∼ 1 - 2 mmHg greater mean IOP lowering than the prostaglandin latanoprost. Bimatoprost is more effective than either timolol or latanoprost in allowing patients to reach the low target pressures that best protect the visual field. Patients on bimatoprost therapy achieve low pressures throughout the day and night. Moreover, 1-year trials have shown that the efficacy of bimatoprost is sustained with long-term use. The most common side effects have been conjunctival hyperaemia, graded as trace or mild, and eyelash growth. No safety concerns have arisen in postmarketing surveillance. Bimatoprost appears to be a valuable new agent for glaucoma therapy.

KW - Bimatoprost

KW - Glaucoma

KW - Intraocular pressure

KW - Ocular hypertension

KW - Prostamide

KW - Target pressure

UR - http://www.scopus.com/inward/record.url?scp=0036931954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036931954&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.12.1753

DO - 10.1517/14656566.3.12.1753

M3 - Article

C2 - 12472372

AN - SCOPUS:0036931954

VL - 3

SP - 1753

EP - 1762

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -